Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
bdtonline.com
news
2022-06-03 20:02:28

LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the 'Company' or 'Freeline') today disclosed the receipt of a notice (the 'Notice') on May 31, 2022 from the Nasdaq Stock Market LLC ('Nasdaq') that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company's American Depositary Shares (the 'ADS') on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the 'Minimum Bid Price Requirement').
